In last trading session, Revance Therapeutics Inc (NASDAQ:RVNC) saw 1.96 million shares changing hands with its beta currently measuring 1.15. Company’s recent per share price level of $3.80 trading at $0.19 or 5.12% at ring of the bell on the day assigns it a market valuation of $395.51M. That closing price of RVNC’s stock is at a discount of -899.47% from its 52-week high price of $37.98 and is indicating a premium of 15.53% from its 52-week low price of $3.21. Taking a look at company’s average trading volume volume of 1.87 million if we extend that period to 3-months.
Revance Therapeutics Inc (NASDAQ:RVNC) trade information
Upright in the green during last session for gaining 5.12%, in the last five days RVNC remained trading in the green while hitting it’s week-highest on Wednesday, 05/01/24 when the stock touched $3.80 price level, adding 6.4% to its value on the day. Revance Therapeutics Inc’s shares saw a change of -56.83% in year-to-date performance and have moved 6.30% in past 5-day. Revance Therapeutics Inc (NASDAQ:RVNC) showed a performance of -15.85% in past 30-days.
Revance Therapeutics Inc (RVNC) estimates and forecasts
Statistics highlight that Revance Therapeutics Inc is scoring comparatively higher than the scores of other players of the relevant industry. The company lost -50.84% of value to its shares in past 6 months, showing an annual growth rate of 43.34% while that of industry is 12.60. Apart from that, the company came raising its revenue forecast for fiscal year 2024. The company is estimating its revenue growth to decrease by -1.40% in the current quarter and calculating 36.30% increase in the next quarter. This year revenue growth is estimated to rise 20.40% from the last financial year’s standing.
7 industry analysts have given their estimates about the company’s current quarter revenue by setting an average figure of $56.63 million for the same. And 7 analysts are in estimates of company making revenue of $68.21 million in the next quarter that will end on Jun 2024. Company posted $49.33 million and $58.13 million of sales in current and next quarters respectively a year earlier. Analysts are expecting this quarter sales to grow by 14.80% while estimating it to be 17.30% for the next quarter.
Weighing up company’s earnings over the past 5-year and in the next 5-year periods, we find the company posting an annual earnings growth rate of 0.57% during past 5 years. In 2024, company’s earnings growth rate is likely to be around 20.20% while estimates for its earnings growth in next 5 years are of 11.60%.
RVNC Dividends
Revance Therapeutics Inc is more likely to be releasing its next quarterly report in June and investors are confident in the company announcing better current-quarter dividends despite the fact that it has been facing issues arising out of mounting debt.
